Travere Therapeutics (TVTX) Invested Capital (2011 - 2026)

Travere Therapeutics has reported Invested Capital for 16 years, with the latest figure at $98.7 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 2.81% year-over-year to $98.7 million; the trailing twelve-month figure through Mar 2026 stood at $98.7 million (down 2.81% YoY), and the FY2025 full-year result was $114.8 million, down 10.12% from the prior year.
• Invested Capital for Q1 2026 stood at $98.7 million, down from $114.8 million in the prior quarter.
• The five-year high for Invested Capital was $279.8 million in Q3 2023, with the low at $15.1 million in Q2 2024.
• Historically, Invested Capital has averaged $122.5 million across 5 years, with a median of $108.0 million in 2022.
• Annual changes were most pronounced in 2024 — Invested Capital slumped 87.72% — and 2025, when it soared 570.66%.
• Travere Therapeutics' Invested Capital stood at $49.9 million in 2022, then jumped by 302.82% to $200.8 million in 2023, then slumped by 36.38% to $127.8 million in 2024, then decreased by 10.12% to $114.8 million in 2025, then declined by 14.02% to $98.7 million in 2026.
• The last three Invested Capital figures came in at $98.7 million (Q1 2026), $114.8 million (Q4 2025), and $73.6 million (Q3 2025), per Business Quant data.